Best Practices for Disease Detection, Risk Stratification, and Treatment Selection in Osteoporosis - POCN
:Home>>Best Practices for Disease Detection, Risk Stratification, and Treatment Selection in Osteoporosis

Best Practices for Disease Detection, Risk Stratification, and Treatment Selection in Osteoporosis

Rheumatology | May 6, 2021

Credits:

0.25 AAPA Category 1 Credit(s)
0.25 AMA PRA Category 1 Credit(s)™
Start Course

Launch Date:

May 6, 2021

Expiration Date:

May 5, 2022

primary audience:

Endocrinologists, Gynecologists, Orthopedists, Primary care physicians, Rheumatologists

Relevant Terms:

Abaloparatide, Bisphosphonate, Bone density, Bone health, Denosumab, Dxa, Fracture, Frax, Osteoporosis, Prevention, Raloxifene, Risk, Romosozumab, Teriparatide, Vitamin d

course faculty

Rachel Pessah-Pollack, MD, FACE

Rachel Pessah-Pollack, MD, FACE, is a Clinical Associate Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at NYU Langone Health, New York, New York.

Dr Pessah-Pollack trained at the Mount Sinai School of Medicine, New York, New York, where she completed her internal medicine residency and endocrinology fellowship. She is board certified in endocrinology, diabetes, and metabolism. She is also board certified as a physician nutrition specialist.

In 2019, Dr Pessah-Pollack was reelected to the American Association of Clinical Endocrinologists (AACE) Board of Directors for her second 3-year term. She has served as chair of the AACE Clinical Practice Guidelines Oversight Committee and chair of the AACE Women’s Leadership Dinner in 2019. She previously served as chair of the American College of Cardiology’s Diabetes Collaborative Registry Stakeholder Advisory Committee from 2018-2019. She has been named a New York Times Super Doctor (2017-2019) and New York Times Super Doctor Rising Star (2014-2016). She is a frequent guest editor of Health Monitor publications for patients and is on the editorial board of Endocrine Today

Dr Pessah-Pollack is a coauthor of numerous peer-reviewed articles and clinical practice guidelines, including the recently published AACE 2020 Postmenopausal Osteoporosis Guidelines. She specializes in metabolic bone disease and lectures nationally on the topic of postmenopausal osteoporosis and fracture prevention. She remains actively involved in medical education and the training of endocrine fellows.

Steven Petak, MD, JD, MACE, FACP

Steven Petak, MD, JD, MACE, FACP, is a clinical and academic endocrinologist in Houston, Texas. He received his medical degree from the University of Illinois in Chicago, Illinois, and his juris doctorate (magna cum laude) from the University of Houston in Houston, Texas. Dr Petak completed his internship, residency, medical chief residency, and fellowship in endocrinology and metabolism at the University of Texas at Houston. He is board certified in internal medicine, endocrinology, and metabolism.

Dr Petak is the division head of endocrinology, diabetes, and metabolism as well as service chief of endocrinology at Houston Methodist Hospital. He is also Associate Clinical Professor at Weill Cornell Medical College at the Houston Methodist Hospital. He was at the Texas Institute for Reproductive Medicine and Endocrinology in Houston for about 26 years before joining the academic endocrine group at Houston Methodist Hospital in May 2013. 

Dr Petak is a past president of the American Association of Clinical Endocrinologists, American College of Endocrinology, and International Society for Clinical Densitometry (ISCD). 

For the past 13 years, Dr Petak has served as a bone densitometry and endocrine consultant to NASA at the Johnson Space Center. He has been part of the bone summit planning long duration space missions. 

Dr Petak is chair of the board of councilors of the Texas Medical Association (2018-2021). His awards include Master of the American College of Endocrinology, Yank Coble Public Service Award of the American College of Endocrinology, Paul Miller ISCD Public Service Award, and ISCD Clinician of the Year. He has authored and coauthored articles, editorials, and guidelines focused on endocrinology and reproductive medicine.

learning objectives
1. DEMONSTRATE appropriate screening approaches for patients who are at risk for osteoporosis, using tools such as Fracture Risk Assessment Tool (FRAX) scoring and dual-energy X-ray absorptiometry (DXA) bone mineral density scans
2. IMPLEMENT accurate diagnostic decision-making based on patient-specific factors and results of tools such as FRAX scoring and DXA bone mineral density scans
3. DESCRIBE updated guideline-recommended osteoporosis treatment algorithms, including risk stratification categories and possible drug treatment options
4. SELECT appropriate patient-specific pharmacologic therapy for osteoporosis based on risk stratification and prior treatment experience
course information

PROVIDERSHIP & SUPPORT
This educational activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Spire Learning.

  

This activity is supported by educational funding provided by Amgen Inc. and Radius Health, Inc. 

PROGRAM OVERVIEW
Are you confident implementing recent osteoporosis recommendations in your clinical practice? Despite clear guidance, screening rates remain suboptimal and many clinicians are hesitant to implement pharmacologic therapy. This 15-minute case-based CE activity, developed by experts Dr Rachel Pessah-Pollack and Dr Steven Petak, addresses screening, diagnosis, treatment strategies, and patient-specific treatment considerations for osteoporosis.

TARGET AUDIENCE
The target audience for this educational initiative is primary care physicians, gynecologists, endocrinologists, rheumatologists, and orthopedists.

LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:

DEMONSTRATE appropriate screening approaches for patients who are at risk for osteoporosis, using tools such as Fracture Risk Assessment Tool (FRAX) scoring and dual-energy X-ray absorptiometry (DXA) bone mineral density scans

IMPLEMENT accurate diagnostic decision-making based on patient-specific factors and results of tools such as FRAX scoring and DXA bone mineral density scans

DESCRIBE updated guideline-recommended osteoporosis treatment algorithms, including risk stratification categories and possible drug treatment options

SELECT appropriate patient-specific pharmacologic therapy for osteoporosis based on risk stratification and prior treatment experience

ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Spire Learning, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation Statements 
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
  

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until May 6, 2022. PAs should only claim credit commensurate with the extent of their participation.

HOW TO RECEIVE CREDIT
To receive credit for your participation in this educational activity:

  • Read the objectives and other introductory CE information
  • Complete the preassessment prior to the start of the activity
  • Participate in the osteoporosis case activity
  • Complete the postassessment and evaluation at the conclusion of the activity

If you are seeking Prescribed credit, you must complete the postassessment and evaluation at the conclusion of the activity.

CONTACT INFORMATION
For questions regarding CE credit, contact AKH Inc., Advancing Knowledge in Healthcare at JGoldman@akhcme.com.

ACCREDITOR DISCLOSURE OF CONFLICTS OF INTEREST STATEMENT
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The planners and faculty must disclose to the participants any significant relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients or with the commercial supporter of this accredited continuing education activity. Identified conflicts of interest are mitigated by AKH prior to the planners/faculty assuming their role in this accredited continuing education activity.

Faculty

Rachel Pessah-Pollack, MD, FACE
Clinical Associate Professor of Medicine
Division of Endocrinology, Diabetes, and Metabolism
NYU Langone Health
New York, NY

Disclosure: Dr Pessah-Pollack has the following relevant disclosures:

Advisory Board: Radius Health, Inc
Advisor: Boehringer Ingelheim; Eli Lilly and Company
Guest Editor: Health Monitor
Content Development: Medscape
Speaker: Cardiometabolic Health Conference

Steven Petak, MD, JD, MACE, FACP
Division Head and Service Chief
Endocrinology, Diabetes, and Metabolism
Associate Clinical Professor
Weill Cornell Medical College
Houston Methodist Hospital
Houston, TX

Disclosure: Dr Petak has the following relevant disclosures:

Speaker: Alexion Pharmaceuticals, Inc; Amgen Inc; Radius Health, Inc

Educational Planning Committee: 
Staff, Planners, and Reviewers

  • Dorothy Caputo, MA, BSN, RN, CE Director of Accreditations/Lead Nurse Planner: No disclosures
  • AKH Inc: No disclosures
  • Spire Learning: Ashton Webb, PharmD, BCACP; Allison Goldberg, MPA; and Lisa Colombo: No relevant financial relationships with any commercial interests.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of Unlabeled Use and Investigational Product 
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
This course is designed solely to provide the health care professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the health care professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

PRIVACY POLICY
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Spire Learning, LLC to continuously improve the learning experience.

Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

COPYRIGHT STATEMENT
Copyright © 2021 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and AKH Inc., Advancing Knowledge in Healthcare will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Microsoft Edge
Google Chrome 60 or higher
Mozilla Firefox 60 or higher
Apple Safari 11.0 or higher
For video, install the latest version of Quicktime.
Supported Phones & Tablets:
iOS 9.3 and higher
Android 7.0 (Nougat or higher)
Microsoft Windows 8
Chrome OS

 

Additional Recommendations and Requirements
Display Resolution & Color Depth Resolution
– 960 X 768 minimum
– 1024 X 768 recommended min.

Color Depth
– 8 bits (256 colors) minimum
– 16 bits (High colors) minimum

Audio – Microphone
– Speakers or headphones
– Audio recording support
Word Processing Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended.

 


Go to Top